Skip to content

Clinical trials

Phase 1 Autoimmune Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autoimmune Diseases Phase: Phase 1 Clear all

169 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20036
20041
20061
20075
20093
20102
20113
20121
20132
20145
20151
20163
20176
20186
20197
20208
202111
202211
20236
202427
202522
202626

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed69
Recruiting43
Not yet recruiting19
Unknown status13
Terminated10
Withdrawn9
Active, not recruiting3
Suspended2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline9
National Institute of Allergy and Infectious Diseases (NIAID)7
Zhejiang University7
The Children's Hospital of Zhejiang University School of Medicine6
Bristol-Myers Squibb4
Changhai Hospital3
Nanjing Legend Biotech Co.3
Beijing Boren Hospital2
CRISPR Therapeutics AG2
Changchun GeneScience Pharmaceutical Co., Ltd.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autoimmune Diseases169
Lupus Erythematosus, Systemic43
Scleroderma, Systemic26
Immune System Diseases16
Arthritis, Rheumatoid15
Myositis15
Multiple Sclerosis13
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis12
Lupus Nephritis12
Sjogren's Syndrome11

Trials

Showing 76 to 100 of 169. Each trial links to its page on Pharma Observatory.

69 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.